Similarly, the KRAS G12C inhibitors sotorasib and JDQ443 had also displayed inhibitory effects on HRAS G12C and NRAS C12C, with the combination therapy of sotorasib and EGFR antibody panitumumab being successfully used to treat a patient with colorectal cancer with NRAS p.G12C mutation (33). Here, KRAS is linked to colorectal cancer.